<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873817</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10347</org_study_id>
    <nct_id>NCT04873817</nct_id>
  </id_info>
  <brief_title>Real-World Outcomes Study on Subjects Treated With Radiofrequency Ablation</brief_title>
  <acronym>ROSTRA</acronym>
  <official_title>Real-World Outcomes Study on Subjects Treated With Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ROSTRA is an international, prospective, non-randomized, single-arm, multi-center, and&#xD;
      post-market study to collect real-world safety and effectiveness data on Abbott's&#xD;
      IonicRF™Generator and compatible RFA accessories. This post-market study is intended to&#xD;
      satisfy EU MDR requirements.&#xD;
&#xD;
      The study will enroll up to 180 subjects at up to 10 sites in Europe and the United States.&#xD;
&#xD;
      The total duration of the study is expected to be 19 months, including enrollment, data&#xD;
      collection from all subjects, and study closeout.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary effectiveness endpoint: Relative change in Numeric Rating Scale (NRS) from baseline to 3 months follow-up visit</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their average pain over the past 24 hours specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Incidence of device- and procedure-related serious adverse events</measure>
    <time_frame>At 3 months</time_frame>
    <description>The device- and procedure-related serious adverse events will be summarized as frequency, proportion and number of events per patient years of follow-up.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>IonicRF Generator and compatible accessories</arm_group_label>
    <description>IonicRF Radiofrequency Generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IonicRF Generator andcompatible accessories</intervention_name>
    <description>Participants will recieve IonicRFRF lesion generator, along with any country-specific market-released accessory (i.e. electrode,cannula, grounding pad, and adaptor cable) compatible with theIonicRF Generator</description>
    <arm_group_label>IonicRF Generator and compatible accessories</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects of all genders from the general chronic pain population referring to the&#xD;
        participating pain clinics will be enrolled in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A. All candidate subjects&#xD;
&#xD;
          1. Subject must provide written informed consent prior to any clinical&#xD;
             investigation-related procedure&#xD;
&#xD;
          2. Subject is ≥ 18 years of age&#xD;
&#xD;
          3. Subject has chronic pain &gt; 6 months and was unresponsive to conservative management&#xD;
&#xD;
          4. Subject has pain on an NRS scale of ≥ 6&#xD;
&#xD;
          5. Subject is scheduled for an RFA procedure with the IonicRF generator within 30 days of&#xD;
             baseline&#xD;
&#xD;
          6. Subject has stable chronic pain medication use for 30 days&#xD;
&#xD;
          7. Subject is willing and able to comply with the prescribed follow-up evaluations&#xD;
&#xD;
        B. Candidate subjects with facet joint pain (lumbar or cervical)&#xD;
&#xD;
          1. Subject has unilateral or bilateral pain on para-spinal palpation&#xD;
&#xD;
          2. Subject has facet joint pain confirmed by at least 1 positive medial branch block with&#xD;
             0.5 mL or less of anesthetics achieving at least 50% pain relief, with real-time&#xD;
             injection of radiographic contrast under fluoroscopic guidance&#xD;
&#xD;
        C. Candidate subjects with sacroiliac joint pain&#xD;
&#xD;
        1. Subject has sacroiliac joint pain confirmed by an infiltration (with bony contact on 3&#xD;
        vertebral levels) of local anesthetics in the posterior part of the sacroiliac joint&#xD;
        achieving at least 50% pain relief&#xD;
&#xD;
        D. Candidate subjects with radicular pain&#xD;
&#xD;
        1. Subject has radicular pain confirmed by sensory mapping across at least 1 vertebral&#xD;
        level&#xD;
&#xD;
        E. Candidate subjects with trigeminal neuralgia&#xD;
&#xD;
          1. Subject has trigeminal pain elicited using a provocation test (e.g. contact with&#xD;
             toothbrush)&#xD;
&#xD;
          2. Subject has sudden, non-continuous pain&#xD;
&#xD;
          3. Subject did not have any mass effect or stroke causing trigeminal pain confirmed by&#xD;
             MRI&#xD;
&#xD;
          4. Subject has attempted anti-neuropathic medication with no improvement of symptoms&#xD;
&#xD;
        F. Candidate subjects with knee or hip pain&#xD;
&#xD;
          1. Subject has radiographically confirmed osteoarthritis of the hip or knee, or has&#xD;
             chronic pain following joint arthroplasty&#xD;
&#xD;
          2. Subject has knee or hip pain confirmed by sensory mapping and/or diagnostic block(s)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A. All candidate subjects&#xD;
&#xD;
          1. Subject is currently participating in another clinical investigation that may confound&#xD;
             the results of this study.&#xD;
&#xD;
          2. Ongoing systemic or local infection in the area of the procedure.&#xD;
&#xD;
          3. Recent use of anticoagulants or subject with coagulopathy.&#xD;
&#xD;
          4. Primary complaint of deafferentation pain.&#xD;
&#xD;
          5. Presence of other anatomic or comorbid conditions, or other medical, social, or&#xD;
             psychological conditions that, in the investigator's opinion, could limit the&#xD;
             subject's ability to participate in the clinical investigation or to comply with&#xD;
             follow-up requirements of the clinical investigation results.&#xD;
&#xD;
          6. Subject's opioid usage is &gt; 90 morphine equivalents per day.&#xD;
&#xD;
        B. Candidate subjects with trigeminal neuralgia&#xD;
&#xD;
        1. Subject has sensory problems&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Jannu</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Gorman</last_name>
    <phone>443-878-7479</phone>
    <email>patrick.gorman1@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Jannu</last_name>
    <phone>512-286-4199</phone>
    <email>ann.jannu@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nevada Advanced Pain Specialists</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Patterson, MD</last_name>
      <email>patterson@nvadvancedpain.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Spine &amp; Nerve Center of St Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Young</last_name>
      <email>Amy.Young@ThomasHealth.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Deer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Neuwerk Maria von den Aposteln</name>
      <address>
        <city>Monchengladbach</city>
        <state>N. Rhin</state>
        <zip>41066</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bjoern Carsten Schultheis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin - Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Kuckuck</last_name>
      <email>anja.kuckuck@charite.de</email>
    </contact>
    <investigator>
      <last_name>Simon Bayerl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo Perez</last_name>
      <email>amparo.perez@inibica.es</email>
    </contact>
    <investigator>
      <last_name>Luis M Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IonicRF™ Generator</keyword>
  <keyword>ABT-CIP-10347</keyword>
  <keyword>Radio frequency ablation (RFA)</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

